Emerging drugs for myelofibrosis. - Wikidata - wikimedia - TriplyDB

Emerging drugs for myelofibrosis.

Emerging drugs for myelofibrosis.

http://www.wikidata.org/entity/Q33404574

about

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.Myelofibrosis, JAK2 inhibitors and erythropoiesis.

P2860

Q37548944-4FC32986-B907-409C-A847-D953A6A6CA18 Q37673351-40B4A2A7-8AB0-4454-99F6-5F1EAE209820 Q44240555-163105EE-69C3-4797-9FE1-9246FF36004A

P2860

Emerging drugs for myelofibrosis.

http://www.wikidata.org/entity/Q33404574

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Emerging drugs for myelofibrosis.

@ast

Emerging drugs for myelofibrosis.

@en

type

label

Emerging drugs for myelofibrosis.

@ast

Emerging drugs for myelofibrosis.

@en

prefLabel

Emerging drugs for myelofibrosis.

@ast

Emerging drugs for myelofibrosis.

@en

P1433

Q33404574-D8D05877-5ABC-4EF9-81DF-16347A925941

P1476

Q33404574-338BE359-501F-482D-9277-B1EBC1ADA0CF

P2093

Q33404574-D277842C-75CE-4342-8975-A4047F660A6C

P2860

Q33404574-1856A749-12CB-4EDA-A1AD-2FFE3288EF16

Q33404574-1C89605A-6D5B-4133-A3FB-7C535C084B0D

Q33404574-1DF6A6B8-DAC2-4B1F-8BC8-44D09BB4B11F

Q33404574-21ADC010-0A46-4E86-92DF-4A9DEBEBC73D

Q33404574-220F64AF-8CDC-47EA-9313-842027355A80

Q33404574-23626801-7567-4875-8C5F-6204EEE212AE

Q33404574-25B7EBA5-9A07-4017-991E-0733432913EB

Q33404574-280DA9C5-D9C1-4124-82D7-0919DD204679

Q33404574-29A70540-097E-453E-9FDF-F35A2D6D3C9F

Q33404574-2A3D88D4-06D9-45C5-95F8-ADA7163A56D3

P304

Q33404574-1C72EDAA-8320-492D-AACF-A528F47AAB05

P31

Q33404574-6c1f1ebc-0dd4-4fa3-8a3c-31dc631f6930

Q33404574-A0298A6E-EB88-4360-8955-7CBE618F01DC

P356

Q33404574-283D2E57-1B07-4B5E-B9F2-1EBC427B8926

P407

Q33404574-B2EE0871-2A0D-469A-BE1D-FE4D082B111A

P433

Q33404574-30BA6335-9F5C-4E37-88C1-408480A3155A

P478

Q33404574-52CF4CA2-DF37-4A83-9FB2-06369466D109

P50

Q33404574-38CCD80F-DE14-4AF8-B839-264D330E4B21

P577

Q33404574-4588C697-A3A3-4FB0-8E66-73979364F812

P698

Q33404574-EFAC9052-EE53-4443-ACA1-D8A0017ACDC7

P932

Q33404574-B197FB2C-922F-4B1B-A7CC-8D3A5DC89F2C

P356

14728214.2012.748748

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging drugs for myelofibrosis.

@en

P2093

Ehab Atallah

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

The Jak-Stat pathway in normal and perturbed hematopoiesis

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

P304

555-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2012.748748

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Srdan Verstovsek

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23186315

http://www.w3.org/2001/XMLSchema#string

P932

5009610

http://www.w3.org/2001/XMLSchema#string